GLP-1 skin and hair changes: what the evidence actually says

What's this video probably claiming?

Based on the caption and creator context, @dr_rey_hamidi is a dermatologist walking through the most common skin changes they see in patients losing weight rapidly on GLP-1 receptor agonists like semaglutide and tirzepatide. The list appears to start with sagging skin and likely continues with other changes, possibly including hair thinning or loss (telogen effluvium), changes in skin texture, dryness, or collagen-related issues. The video is structured as a teaser to drive newsletter sign-ups and DMs, which means it is probably omitting specifics in favor of generating engagement. The hashtags antiaging and skincare suggest the video frames at least some of these changes in an aesthetic or preventative context, not just clinical documentation. That framing is worth watching carefully, because the jump from observed clinical patterns to actionable skin and hair interventions is where influencer medicine tends to get ahead of the data.

What does the science actually show?

Rapid weight loss from any cause, including GLP-1-mediated weight loss, is well-documented to produce skin laxity, particularly in the face, neck, arms, and abdomen. A 2023 analysis tied to the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) noted that participants lost an average of 20.9% of body weight on tirzepatide over 72 weeks, a rate fast enough to outpace skin elasticity recovery. Telogen effluvium, the stress-related diffuse hair shedding that follows physiological shocks including rapid caloric restriction, is also real and documented in bariatric surgery literature dating back decades. A 2020 review by Asghar et al. in the Journal of the European Academy of Dermatology and Venereology confirmed that hair loss post-bariatric surgery affects up to 57% of patients, with onset typically at 3 to 6 months post-surgery. Whether GLP-1-specific mechanisms beyond caloric restriction contribute to these changes is still an open question. Protein and micronutrient deficiency, not the drug itself, appears to drive most of the dermatological findings.

Where does the social media noise diverge from clinical reality?

The biggest divergence is the implied message that there is a curated, intervention-ready protocol to counteract GLP-1 skin and hair changes, and that you need to follow a newsletter to access it. The honest clinical picture is less tidy. Skin laxity after significant weight loss is largely structural, driven by reduced subcutaneous fat volume and collagen remodeling, and topical products have limited evidence for reversing it. A 2021 Cochrane-adjacent systematic review on non-surgical interventions for skin laxity found weak and inconsistent evidence across radiofrequency, collagen supplements, and retinoid-based protocols. Hair loss from telogen effluvium typically resolves on its own within 6 to 12 months without intervention, provided nutritional adequacy is maintained. The risk in videos like this one is that patients start spending money on supplements or procedures marketed to GLP-1 users when watchful waiting and adequate protein intake are the most evidence-supported recommendations available right now.

What should you actually know?

If you are on a GLP-1 and noticing skin or hair changes, a few things are worth understanding. First, the rate of weight loss matters more than the drug itself. Losing more than 1 to 1.5 pounds per week consistently accelerates skin laxity and nutritional depletion. Second, protein intake is genuinely important during GLP-1-assisted weight loss. The STEP trials did not mandate dietary protocols, but researchers like Aronne et al. have consistently flagged lean mass preservation as a concern when protein falls below 1.2 grams per kilogram of body weight. Third, telogen effluvium from GLP-1 use has limited dedicated trial data. Most claims extrapolate from bariatric surgery literature, which involves more invasive physiological disruption. Fourth, if a dermatologist is recommending specific products or procedures for GLP-1 skin changes without citing clinical data, ask for the study. The field is early and the influencer economy around Ozempic and Mounjaro is moving faster than the published literature.